Be the first to like this
Based in New York City, Keryx Biopharmaceuticals, Inc., develops and markets pharmaceuticals for the treatment of patients with renal disease. In January 2013, the company completed phase three trials for the drug ferric citrate for the treatment of hyperphosphatemia (elevated phosphate levels in the blood) in patients living with chronic end-stage kidney disease. Marketed as Zerenex, ferric citrate is also in phase two trials for its use in stabilizing serum phosphorus levels and increasing iron stores in the blood of patients with both anemia and non-dialysis dependent chronic renal disease. Additionally, Keryx Biopharmaceuticals partners are currently seeking approval to market the drug in Japan.
Early supporters of Keryx Biopharmaceuticals include biotechnology investor Lindsay Rosenwald, MD, who heads Opus Point Partners as cofounder. Dr. Lindsay Rosenwald formerly served as a director and member of the company’s Board of Directors, stepping down in November 2008 to focus on other business undertakings. As of the present date, board members include Chairman Michael Tarnok, Jack Kaye, and Kevin Cameron.